Characterization of the von Willebrand factor/factor VIII complex produced by a novel purification process

Area of Science:

• Hematology
• Biochemistry
• Protein Purification

Background:

• Factor VIII (FVIII) is crucial for blood coagulation, complexed with von Willebrand factor (vWF) in plasma.
• Previous studies (SIPPET) indicated plasma-derived FVIII with vWF is less immunogenic than high-purity or recombinant FVIII.
• Conventional FVIII purification methods result in low vWF content, potentially increasing immunogenicity.

Purpose of the Study:

• To develop a purification method to increase vWF content in FVIII preparations.
• To create a vWF/FVIII complex with high molecular weight vWF and reduced FVIII inhibitor reactivity.
• To evaluate the efficacy and immunogenicity of the novel vWF/FVIII complex in a hemophilia A mouse model.

Main Methods:

• Recovered purified vWF from anion-exchange (AEX) chromatography washing solutions using cation-exchange (CEX) chromatography.
• Reconstituted purified FVIII with the recovered purified vWF to create a vWF/FVIII complex.
• Assessed the vWF content, vWF multimer distribution, and FVIII inhibitor reactivity of the complex.
• Evaluated the therapeutic efficacy in a mouse model of hemophilia A.

Main Results:

• The new purification method successfully produced a vWF/FVIII complex with abundant high molecular weight vWF, similar to normal plasma.
• The reconstituted complex demonstrated low reactivity with FVIII inhibitors.
• The vWF/FVIII complex showed efficacy in a mouse model of hemophilia A.

Conclusions:

• The novel purification method yields a vWF/FVIII complex with desirable characteristics for hemophilia A treatment.
• This vWF/FVIII complex is potentially less immunogenic and therapeutically effective for hemophilia A and von Willebrand disease.
• The method offers a promising strategy for producing improved FVIII-based therapeutics.